🩸 Iron deficiency occurs when the body does not have enough stored iron.
Worldwide, about 2 billion people have #irondeficiency and 1.2 billion people have iron-deficiency #anemia.
Learn more in this JAMA Patient Page: https://t.co/pUQASjLMyl
Great post from #stevanbruijns on a paper exploring how moral injury affects emergency staff. Lots here for EM to understand and hopefully correct.
JC: Moral Injury Emergency Medicine https://t.co/ko1Ew5kxih
🎙️ In this podcast episode, author David Kent, MD, MS, of @TuftsMedicine and JAMA Associate Editor David Simel, MD, MHS, discuss how to evaluate the likelihood that a PFO was causal in a patient with a cryptogenic ischemic stroke.
🎧 Listen now: https://t.co/973zY7jmUM
Mild isolated functional VWF defects in the 30 to 50 IU/dL range are common and are associated with significant bleeding in some patients. https://t.co/x0GLhfLHPq #thrombosisandhemostasis#clinicaltrialsandobservations
💡 #TransfusionTuesday
Do patients actually receive the fibrinogen we intend in massive transfusion? Modeling shows important gaps to address.
🔗 https://t.co/3S7ZgTXCXO
#Hemostasis#THOR#RDCR
This week 4 students screened 233 women 1 in 3 had heavy periods and 21% anaemia - yet there is no national screening program - anywhere - what if men had periods ?
🔍 Thrombophilia testing? Knowing when and how to test is crucial — but so is knowing which lab to trust.
The latest ISTH SSC guidance outlines best practices and recommendations for lab selection and testing reliability.
Read it👇Share it Apply it #ISTH2025#Hemostasis
In a study published in NEJM involving more than 1700 patients with cancer-related VTE, reduced-dose apixaban (2.5 mg twice daily) resulted in similar 12-month VTE recurrence rates compared with full-dose (5 mg twice daily) apixaban (2.1 versus 2.8 per cent). However, fewer patients receiving reduced-dose apixaban experienced clinically significant bleeding compared with patients receiving full-dose apixaban (12.1 per cent versus 15.6 per cent).
@NEJM
The much used @RCObsGyn Greentop guideline 37a is being revised. Here is a @BJOGTweets commentary from @LauraAMagee1 and the guideline update committee. In the journal https://t.co/yoviwrdbJh and on video https://t.co/ijc0iSB7Rc
My favorite talk of the day at @theTHORnetwork#THOR2025, expertly delivered by @gael_beverley, on blood product and fibrinogen concentrate manufacturing - cryo appears to be the better product than concentrate but still equipoise as to when and how to use it in trauma
As a women’s health Haematologist I am passionate about advocating for change when it comes to Heavy Menstrual Bleeding (HMB).
1 in 4 women experience HMB.
1 in 2 will be iron deficient, or iron deficient anaemic.
#ihmbday#ihmbday2025#heavymenstrualbleeding#bleedbetter
🔥 Hot off the press: the latest issue of Transfusion is a special supplement dedicated to the 2025 THOR Meeting!
Cutting-edge science in trauma, hemorrhage control, blood products, oxygenation & beyond.
Read here 👉 https://t.co/lHnoq2ODhh
#THOR2025#TraumaResearch
AJOG Expert Review: The maternal-fetal interface at single-cell resolution: uncovering the cellular anatomy of the placenta and decidua https://t.co/WhJyqMhnSt